NO166485C - Analogifremgangsmaate for fremstilling av terapeutisk aktive 4h-pyrrolo(3,3-d)-pyrimidin-4-oner. - Google Patents

Analogifremgangsmaate for fremstilling av terapeutisk aktive 4h-pyrrolo(3,3-d)-pyrimidin-4-oner.

Info

Publication number: NO166485C
Authority: NO; Norway
Prior art keywords: pyrrolo; oner; pyrimidin; preparation; therapeutic active
Prior art date: 1986-08-26

Application number

NO87873584A

Other languages

English (en)

Norwegian (no)

Other versions

NO873584L (no

NO873584D0 (no

NO166485B (no

Inventor

Catherine Rose Kostlan

Jagadish Chandra Sircar

Original Assignee

Warner Lambert Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-08-26

Filing date

1987-08-25

Publication date

1991-07-31

1987-08-25 Application filed by Warner Lambert Co filed Critical Warner Lambert Co

1987-08-25 Publication of NO873584D0 publication Critical patent/NO873584D0/no

1988-02-29 Publication of NO873584L publication Critical patent/NO873584L/no

1991-04-22 Publication of NO166485B publication Critical patent/NO166485B/no

1991-07-31 Publication of NO166485C publication Critical patent/NO166485C/no

Links

238000000034 method Methods 0.000 title abstract 2
230000001225 therapeutic effect Effects 0.000 title 1
YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 abstract 1
YKBGVTZYEHREMT-UHFFFAOYSA-N 2'-deoxyguanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1CC(O)C(CO)O1 YKBGVTZYEHREMT-UHFFFAOYSA-N 0.000 abstract 1
208000023275 Autoimmune disease Diseases 0.000 abstract 1
201000005569 Gout Diseases 0.000 abstract 1
KCTZOTUQSGYWLV-UHFFFAOYSA-N N1C=NC=C2N=CC=C21 Chemical class N1C=NC=C2N=CC=C21 KCTZOTUQSGYWLV-UHFFFAOYSA-N 0.000 abstract 1
101710101148 Probable 6-oxopurine nucleoside phosphorylase Proteins 0.000 abstract 1
201000004681 Psoriasis Diseases 0.000 abstract 1
102000030764 Purine-nucleoside phosphorylase Human genes 0.000 abstract 1
210000001744 T-lymphocyte Anatomy 0.000 abstract 1
210000003719 b-lymphocyte Anatomy 0.000 abstract 1
231100000433 cytotoxic Toxicity 0.000 abstract 1
230000001472 cytotoxic effect Effects 0.000 abstract 1
VGONTNSXDCQUGY-UHFFFAOYSA-N desoxyinosine Natural products C1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 VGONTNSXDCQUGY-UHFFFAOYSA-N 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
238000002054 transplantation Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Pain & Pain Management (AREA)
Immunology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Compositions Of Macromolecular Compounds (AREA)
Anti-Oxidant Or Stabilizer Compositions (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Luminescent Compositions (AREA)
Compounds Of Unknown Constitution (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

NO87873584A 1986-08-26 1987-08-25 Analogifremgangsmaate for fremstilling av terapeutisk aktive 4h-pyrrolo(3,3-d)-pyrimidin-4-oner. NO166485C (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US90048686A	1986-08-26	1986-08-26
US5941987A	1987-06-18	1987-06-18

Publications (4)

Publication Number	Publication Date
NO873584D0 NO873584D0 (no)	1987-08-25
NO873584L NO873584L (no)	1988-02-29
NO166485B NO166485B (no)	1991-04-22
NO166485C true NO166485C (no)	1991-07-31

Family

ID=26738724

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO87873584A NO166485C (no)	1986-08-26	1987-08-25	Analogifremgangsmaate for fremstilling av terapeutisk aktive 4h-pyrrolo(3,3-d)-pyrimidin-4-oner.

Country Status (16)

Country	Link
EP (1)	EP0260491B1 (de)
JP (2)	JP2595254B2 (de)
KR (2)	KR940008421B1 (de)
AT (1)	ATE67203T1 (de)
AU (1)	AU619724B2 (de)
CA (2)	CA1293727C (de)
DE (1)	DE3772913D1 (de)
DK (1)	DK169705B1 (de)
ES (1)	ES2038635T3 (de)
FI (1)	FI85856C (de)
GR (1)	GR3002697T3 (de)
IE (1)	IE60433B1 (de)
NO (1)	NO166485C (de)
NZ (1)	NZ221463A (de)
PH (1)	PH24669A (de)
PT (1)	PT85582B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1294960C (en) *	1986-10-24	1992-01-28	Thomas C. Malone	7-deazaguanines as immunomodulators
RU2093513C1 (ru) *	1989-02-27	1997-10-20	Биокрайст Фармасьютикалз Инк.	Производные 9-деазагуанины или их таутомеры и фармацевтическая композиция, обладающая способностью ингибировать активность пуриннуклеозид фосфорилазы у млекопитающих
CA2072123C (en) *	1989-10-31	2001-06-12	John A. Secrist, Iii	Inhibitors of purine nucleoside phosphorylase
US5726311A (en) *	1989-11-29	1998-03-10	Biocryst Pharmaceuticals, Inc.	7-disubstituted-methyl-4-oxo-3H,5H-pyrrolo 3,2-d!pyrimidine and pharmaceutical uses and compositions containing the same
AU6855594A (en) *	1993-06-30	1995-01-24	Biocryst Pharmaceuticals, Inc.	9-deazahypoxanthines as pnp inhibitors
US5386031A (en) *	1993-12-15	1995-01-31	Warner-Lambert Company	Process for the synthesis of 2-amino-3,5-dihydro-7-substituted-4H-pyrrolo[3,]pyrimidin-4-ones
FI971413L (fi) *	1994-10-05	1997-04-04	Chiroscience Ltd	Puriini- ja guaniiniyhdisteet PNP:n estäjinä
FR2728181B1 (fr) *	1994-12-16	1997-01-31	Appryl Snc	Composante catalytique pour la polymerisation des olefines, son procede de fabrication, et procede de polymerisation des olefines en presence de ladite composante catalytique
JP3290666B2 (ja) *	1995-06-07	2002-06-10	ファイザー・インコーポレーテッド	複素環式の縮合環ピリミジン誘導体
US6395733B1 (en)	1995-06-07	2002-05-28	Pfizer Inc	Heterocyclic ring-fused pyrimidine derivatives
NZ523970A (en) *	2003-02-04	2005-02-25	Ind Res Ltd	Process for preparing inhibitors of nucleoside phoshorylases and nucleosidases
KR20060120069A (ko) *	2003-10-03	2006-11-24	쓰리엠 이노베이티브 프로퍼티즈 컴파니	피라졸로피리딘 및 그의 유사체
NZ540160A (en) *	2005-05-20	2008-03-28	Einstein Coll Med	Inhibitors of nucleoside phosphorylases
GB201417165D0 (en) *	2014-09-29	2014-11-12	Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin	Treatments for Autoimmune Disease
GB201417163D0 (en)	2014-09-29	2014-11-12	Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin	Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IN164556B (de) *	1986-03-06	1989-04-08	Takeda Chemical Industries Ltd
CA1294960C (en) *	1986-10-24	1992-01-28	Thomas C. Malone	7-deazaguanines as immunomodulators
DE3739366A1 (de) *	1987-04-10	1988-10-27	Boehringer Mannheim Gmbh	Desaza-purin-nucleosid-derivate, verfahren zu deren herstellung sowie deren verwendung bei der nucleinsaeure-sequenzierung sowie als antivirale mittel

1987
- 1987-07-30 IE IE207087A patent/IE60433B1/en not_active IP Right Cessation
- 1987-07-30 CA CA000543431A patent/CA1293727C/en not_active Expired - Fee Related
- 1987-08-17 NZ NZ221463A patent/NZ221463A/xx unknown
- 1987-08-24 FI FI873648A patent/FI85856C/fi not_active IP Right Cessation
- 1987-08-24 PH PH35723A patent/PH24669A/en unknown
- 1987-08-24 DK DK440287A patent/DK169705B1/da not_active IP Right Cessation
- 1987-08-25 ES ES87112339T patent/ES2038635T3/es not_active Expired - Lifetime
- 1987-08-25 EP EP87112339A patent/EP0260491B1/de not_active Expired - Lifetime
- 1987-08-25 DE DE8787112339T patent/DE3772913D1/de not_active Expired - Fee Related
- 1987-08-25 NO NO87873584A patent/NO166485C/no unknown
- 1987-08-25 JP JP62209423A patent/JP2595254B2/ja not_active Expired - Fee Related
- 1987-08-25 AT AT87112339T patent/ATE67203T1/de not_active IP Right Cessation
- 1987-08-25 AU AU77416/87A patent/AU619724B2/en not_active Ceased
- 1987-08-25 PT PT85582A patent/PT85582B/pt not_active IP Right Cessation
- 1987-08-26 KR KR1019870009320A patent/KR940008421B1/ko not_active Expired - Fee Related
1991
- 1991-03-07 CA CA000616019A patent/CA1320203C/en not_active Expired - Fee Related
- 1991-09-12 GR GR91401215T patent/GR3002697T3/el unknown
1994
- 1994-06-08 KR KR1019940012787A patent/KR940008848B1/ko not_active Expired - Fee Related
1996
- 1996-06-05 JP JP8142606A patent/JP2650644B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
KR940008421B1 (ko)	1994-09-14
KR940008848B1 (ko)	1994-09-28
JP2650644B2 (ja)	1997-09-03
NZ221463A (en)	1990-07-26
JP2595254B2 (ja)	1997-04-02
PT85582B (pt)	1990-05-31
DK169705B1 (da)	1995-01-16
FI85856C (fi)	1992-06-10
CA1320203C (en)	1993-07-13
PT85582A (en)	1987-09-01
PH24669A (en)	1990-09-07
JPS6388185A (ja)	1988-04-19
EP0260491A1 (de)	1988-03-23
AU7741687A (en)	1988-03-03
FI873648A7 (fi)	1988-02-27
AU619724B2 (en)	1992-02-06
NO873584L (no)	1988-02-29
KR880002873A (ko)	1988-05-12
DE3772913D1 (de)	1991-10-17
JPH08311040A (ja)	1996-11-26
NO873584D0 (no)	1987-08-25
DK440287A (da)	1988-02-27
IE60433B1 (en)	1994-07-13
DK440287D0 (da)	1987-08-24
FI85856B (fi)	1992-02-28
EP0260491B1 (de)	1991-09-11
IE872070L (en)	1988-02-26
CA1293727C (en)	1991-12-31
ATE67203T1 (de)	1991-09-15
ES2038635T3 (es)	1993-08-01
NO166485B (no)	1991-04-22
GR3002697T3 (en)	1993-01-25
FI873648A0 (fi)	1987-08-24

Publication	Publication Date	Title
NO166485C (no)	1991-07-31	Analogifremgangsmaate for fremstilling av terapeutisk aktive 4h-pyrrolo(3,3-d)-pyrimidin-4-oner.
MY104043A (en)	1993-10-30	Therapeutic nucleosides.
DE69432087D1 (de)	2003-03-06	6-Amino-purinderivate mit PDE-IV inhibierender Wirkung
AU591125B2 (en)	1989-11-30	Therapeutic nucleosides
AU4690989A (en)	1990-06-21	Antiviral cytosine and guanine derivatives
NO168423C (no)	1992-02-19	Analogifremgangsmaate for fremstilling av terapeutisk aktive bis-(hydroksymetyl) -cyklobutylpuriner og -pyrimidiner
ATE296309T1 (de)	2005-06-15	Wasserlösliche adenosin kinase inhibitoren
ATE282628T1 (de)	2004-12-15	Oral aktive adenosinkinase-inhibitoren
MY104575A (en)	1994-04-30	Therapeutic nucleosides.
LV5273A3 (lv)	1993-10-10	Panemiens pirimidinnukleozidu iegusanai
DK322189A (da)	1989-06-28	Imidazo(1,2-a)-(pyridaziner eller pyraziner) til behandling af sygdomme med relation til knogletab
ATE63747T1 (de)	1991-06-15	Antivirale verbindungen.
NO171067C (no)	1993-01-20	Analogifremgangsmaate for fremstilling av terapeutisk aktive 4,5-dihydro- og 4,5,6,7-tetrahydro-pyrazolo (1,5-a)pyrimidiner
NO167028C (no)	1991-09-25	Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrazolo(3,4-d)pyrimidinderivater
EP0351215A3 (de)	1991-08-14	Ester von 9-(2-Hydroxyethoxymethyl)guanin
AU2527688A (en)	1989-04-18	Artificial dna base pair analogues
MY103593A (en)	1993-08-28	Bicyclic compounds, their use as pharmaceuticals, their preparation, and intermediates useful in their preparation
HU896136D0 (en)	1990-02-28	Process for producing compounds with antiviral effect and pharmaceutical compositions comprising same
FI884595A7 (fi)	1989-04-07	Menetelmä terapeuttisesti käyttökelpoisten imidatso/1,5-a/tieno/3,2-d/- ja -/3,2-e/pyrimidiinien valmistamiseksi
ES2062351T3 (es)	1994-12-16	Derivados de triazolo (4,5-c) piridina anticonvulsivos.
NO163530C (no)	1990-06-13	Analogifremgangsmaate for fremstilling av terapeutisk aktive 6-substituerte-5-fenyltetrazolo-(1,5-a) (1,2,4)-triazolo(1,5-c)pyrimidiner.